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Recent progress in chemotherapy has prolonged the survival of patients with malignant biliary strictures, leading to 
increased rates of stent occlusion. Even we employed metallic stents which contributed to higher rates and longer durations 
of patency, and occlusion of covered metallic stents now occurs in about half of all patients during their survival. We 
investigated the complication and patency rate for the removal of covered metallic stents, and found that the durations 
were similar for initial stent placement and re-intervention. In order to preserve patient quality of life, we currently 
recommend the use of covered metallic stents for patients with malignant biliary obstruction because of their removability 
and longest patency duration, even though uncovered metallic stents have similar patency durations.
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INTRODUCTION
Since the initial report by Soehendra et al. (1), the 
outcomes of endoscopic retrograde biliary drainage have 
improved considerably with the development of large-
bore, metallic, and covered metallic stents. However, this 
improvement has contributed to higher rates and longer 
patency durations (2-11). Recent progress in chemotherapy 
has prolonged the survival of patients with unresectable 
malignant tumors associated with biliary obstruction (12-
15). The patency period of even metallic stents is shorter 
than required, and about half of all patients now require 
the placement of 2 or 3 stents during their lifetime. 
Many studies concerning the management of occluded 
or dislocated biliary stents have been reported (16-22). 
Mechanical cleaning with a balloon and “stent-in-stent” 
placement with a plastic tube or other devices have been 
performed, but the patency duration was rather short. The 
removal of metallic stents has been sporadically reported, 
suggesting that stent removal followed by replacement may 
be one way to manage occluded or dislocated stents (23-
29). We investigated the patency durations and rates of the 
first stent as well as re-intervention, success rates of stent 
removal, and complications, especially for the management 
of patients with malignant biliary obstruction who have 
survived more than the stent patency duration.
Necessity of Stent Exchange
Remarkable progress has been recently made in the 
chemotherapy and radiotherapy of unresectable malignant 
tumors of the biliary tract and pancreas, which has led to Korean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S63
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increasing numbers of long-term survivors. Although the 
patency duration of metallic stents has been prolonged, the 
patency duration of a single stent is often too short, and 
the number of patients who clinically require the placement 
of second or third metallic stents is increasing. According 
to our data, the stent-occlusion rate was 36.0% (67/186) 
overall and 49.0% (67/137) among the survivors. Thus, 
nearly half of all surviving patients had a stent occlusion. 
The main causes of stent occlusion were debris or food 
residue (25 patients, 37%), dislocation (13 patients, 19%), 
and migration with hyperplasia (13 patients, 19%) (Tables 1, 
2) (35).
Historical Review of Stent Management
Stent occlusion due to debris or food residue is usually 
treated by lavage with a balloon-tipped catheter or a 
“stent-in-stent” procedure. Previous studies reported 
that the stent patency duration was 21 to 34 days after 
mechanical lavage with a balloon-tipped catheter, 90 days 
after the placement of a plastic stent in an self-expandable 
metal stent (SEMS), and 75 to 192 days after a “stent-in-
stent” placement of a SEMS (17, 18). The patency duration 
after these procedures was slightly shorter than after 
placement of the initial SEMS. However, because SEMSs 
have the longest patency duration, they are considered 
clinically useful for the treatment of initial stent occlusion 
(17, 18, 33). From the viewpoint of cost effectiveness and 
patient quality of life, SEMSs are also recommended as the 
second stent (34).
Metallic Stent Removal
Ideally, the first metallic stent should be removed and 
then replaced by an SEMS. In previous studies, stent 
removal was performed only if a stent was misplaced soon 
after placement. This procedure was considered risky and 
was unsuccessful in many patients (16). In subsequent 
studies, stents were removed or cut to treat complications 
such as ulcers or stent occlusion due to migration or 
dislocation. In the case reports, laser treatment (19), 
forceps (24), suture-cutting devices (26), snares (25, 28), 
and argon plasma coagulation (20-23) have been used to 
remove or cut stents. 
In 2004, Kahaleh et al. (29) reported the results of stent 
removal in a series of 18 patients. The period of time from 
stent placement to removal ranged from 1 week to 16 
months in 4 patients with uncovered SEMSs and 1 to 11 
months in 14 with covered SEMSs. In prospective studies, 
Familiari et al. (31) and Shin et al. (32) reported that 0% to 
38.4% of uncovered SEMSs and 86.4% to 92.3% of covered 
SEMSs could be removed with no serious complications.
According to our data, we have attempted metallic stent 
removal in 50 cases and 78.0% (39/50) of the covered 
SEMSs could be removed (35) (Fig. 1). Ten stents had 
migrated into the bile duct and had hyperplastic-tissue 
ingrowth of the uncovered portion at the distal end of the 
SEMS, and 1 stent that had remained in place for 2 years 
5 months and was suspected to have tumor ingrowth and 
could not be removed. Our results and those of previous 
studies suggest that a covered Wallstent or Wallflex 
stent can be removed within 1.0-1.5 years after initial 
placement if there is no stent migration with hyperplastic-
tissue ingrowth of the uncovered portion. Even stents with 
hyperplastic-tissue ingrowth of the uncovered portion could 
be removed if the stent slightly protruded towards the 
duodenum, allowing the protruding portion to be grasped 
with a snare. The hyperplastic tissue inside the stent was 
then incised with a needle knife, allowing the stent to be 
removed with the snare. Another technique so called the 
“inversion technique”, in which the inner end of the stent 
Table 1. Complications Associated with First Covered 
Metallic Stent (Endoscopy 2011;43:1039-1044)
Stent occlusion rate (in patients)  36% (67/186)
Stent occlusion rate (survivors)  49% (67/137)
Cholecystitis    7% (13/186)
Post-ERCP pancreatitis    3% (6/186)
Stent-induced ulcer    3% (5/186)
Liver abscess    1% (2/186)
Cholangitis    1% (2/186)
Perforated duodenal ulcer 0.5% (1/186)
Note.— ERCP = endoscopic retrograde 
cholangiopancreatography
Table 2. Causes of Occlusion of First Covered Metallic 
Stent (total n = 67) (Endoscopy 2011;43:1039-1044)
Debris 25 (37%)
Dislocation 13 (19%)
“Migration + hyperplasia” 13 (19%)
Overgrowth   6 (9%)
Ingrowth   2 (3%)
Axial force   1 (1.5%)
Unknown   7 (10%)Korean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S64
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is caught by forceps and removed. Futhermore, the problem 
of hyperplastic-tissue ingrowth may be solved if we employ 
a “full covered” stent.
In order to prevent stent migration, it was reported that 
stents one size longer than the length was required (32). 
We also inserted longer metallic stents measuring 6 or 8 cm 
in length in most patients because the axial force of a 4-cm 
metallic stent has caused biliary obstruction. Nonetheless, 
proximal migration with hyperplasia occurred in 19% of 
cases; however, we should emphasize that none of the 
second stents have shown proximal migration at the time of 
this writing.
Using a duodenal endoscope with a 3.7-mm channel, most 
stents could be removed through the channel by snaring 
the stent (Fig. 1). Furthermore, all stents could be removed 
when a duodenal endoscope with a 4.2-mm channel was 
used. Removal of a Wallflex stent might require the use of a 
duodenal endoscope with a 4.2-mm channel.
Re-Intervention with a Metallic Stent
Ornellas et al. (33) compared 48 patients with initially 
placed covered SEMSs with 56 different patients on 
their second stents and found that the patency duration 
did not differ significantly between the groups (p = 
0.057). However, the initial placement group included a 
significantly higher proportion of patients with advanced 
disease, whereas the re-intervention group included a 
significantly higher proportion of patients with proximal 
biliary strictures.
We also studied the effectiveness of primary stent 
placement, as well as the effectiveness and safety of 
secondary stent placement (re-intervention) in patients 
with unresectable malignant biliary obstructions (35). 
In our study, there was no difference in demographic 
characteristics between the initial placement group and the 
re-intervention group, and all patients in the latter group 
were included in the former. Because a longer time had 
elapsed since the diagnosis in the re-intervention group, 
the disease stage was more advanced than at the time of 
initial placement. However, demographic characteristics 
such as age, sex, and underlying disease were similar in 
these groups. The patency rates and patency durations 
also did not differ significantly between these groups (p = 
0.08) (Fig. 2). There was also no significant difference in 
the patency rates and patency durations between initially 
placed stents and secondarily placed stents in the same 
patients (p = 0.07) (Fig. 3). Although the patency durations 
Fig. 1. Distal end of Covered SEMS was caught by snare and removed through duodenal endoscope channel.
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Fig. 2. Kaplan-meier curves comparing cumulative patency of 
first and second metallic stents in all 186 cases (Endoscopy 
2011;43:1039-1044). MPT = median patency timeKorean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S65
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of the first stent in the removed group, where the first 
stents were removed and a second stent was inserted, was 
shorter than that of all the first stents and hence must be 
biased. Therefore, we also compared the patency durations 
of the second stents with all the first stents, and a log-rank 
analysis confirmed the lack of a significant difference (Figs. 
2, 3).
CONCLUSIONS
A consensus has not been reached as to whether covered 
metallic stents have a significantly longer patency duration 
than uncovered metallic stents (7-11). Futhermore, covered 
metallic stents are also considered to have a significantly 
higher risk of migration and dislocation (9-11). However we 
confirmed that stents could be removed easily and safely. 
Given that further prolongation of the patency duration is 
unlikely in the foreseeable future, covered metallic stents 
are best suited for re-intervention because they have the 
longest durations of patency.
We believe that our results have important implications 
for clinical practice. However, additional prospective studies 
comparing re-interventions after the removal of metallic 
stents with “stent-in-stent” placement of metallic stents 
are needed. Studies with a larger number of patients are 
also necessary. At present, the covered metallic stents 
can be relatively easily reinserted after the removal of the 
initially placed covered metallic stents, without causing 
complications. Patency rates and durations of the second 
stents are similar to those of the initially placed stents. To 
preserve patient quality of life, we currently recommend 
covered metallic stents for patients with malignant biliary 
obstruction because of their removability and longest 
durations of patency, although uncovered metallic stents 
have similar patency durations.
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